The effects of magnesium-zinc-calcium-vitamin D co-supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes.
Study Goal
The researchers aimed to determine the effects of magnesium-zinc-calcium-vitamin D co-supplementation on inflammation, oxidative stress, and pregnancy outcomes in women with gestational diabetes.
Results Summary
The co-supplementation significantly reduced inflammation and oxidative stress markers (hs-CRP and MDA) and increased antioxidant capacity. It also showed a trend toward reducing newborn weight and macrosomia rates.
Population
60 women with gestational diabetes not taking oral hypoglycemic agents.
Effective Dosage
Not specified
Duration
6 weeks
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
magnesium-zinc-calcium-vitamin D co-supplementation | decrease | serum high-sensitivity C-reactive protein | women with GDM | - 1.2 ± 3.5 vs. + 0.8 ± 2.0 mg/L | resulted in a significant reduction | #1 |
magnesium-zinc-calcium-vitamin D co-supplementation | decrease | plasma malondialdehyde concentrations | women with GDM | - 0.3 ± 0.3 vs. + 0.3 ± 1.1 μmol/L | resulted in a significant reduction | #2 |
magnesium-zinc-calcium-vitamin D co-supplementation | increase | total antioxidant capacity levels | women with GDM | + 38.2 ± 76.5 vs. -16.3 ± 93.5 mmol/L | resulted in a significant increase | #3 |
magnesium-zinc-calcium-vitamin D co-supplementation | decrease | newborns' weight | women with GDM | 3089.8 ± 519.9 vs. 3346.3 ± 411.1 g | found a decreasing trend | #4 |
magnesium-zinc-calcium-vitamin D co-supplementation | decrease | rate of macrosomia | women with GDM | 3.3% vs. 16.7% | found a decreasing trend | #5 |
magnesium-zinc-calcium-vitamin D co-supplementation | decrease | biomarkers of inflammation and oxidative stress | women with GDM | - | may reduce | #6 |
BACKGROUND: Diabetes is the most common medical condition in pregnant women and its complications affect both mother and fetus. The beneficial effects of vitamin D on gestational diabetes have been shown, though data on the effects of co-administration of vitamin D with other nutrients on pregnancy outcomes in gestational diabetes (GDM) are scarce. This study was aimed to determine the effects of magnesium-zinc-calcium-vitamin D co-supplementation on parameters of inflammation and oxidative stress, and pregnancy outcomes among women with GDM. METHODS: This randomized, double-blinded, placebo-controlled trial was conducted on 60 women with GDM not taking oral hypoglycemic agents. Patients were randomly assigned to take magnesium-zinc-calcium-vitamin D supplements (n = 30) or placebo (n = 30) for 6 weeks. Fasting blood samples were collected from participants at baseline and after the 6-week intervention to measure related biomarkers. RESULTS: Magnesium-zinc-calcium-vitamin D co-supplementation resulted in a significant reduction in serum high-sensitivity C-reactive protein (- 1.2 ± 3.5 vs. + 0.8 ± 2.0 mg/L, P = 0.01) and plasma malondialdehyde concentrations (- 0.3 ± 0.3 vs. + 0.3 ± 1.1 μmol/L, P = 0.003), as well as a significant increase in total antioxidant capacity levels (+ 38.2 ± 76.5 vs. -16.3 ± 93.5 mmol/L, P = 0.01), compared to placebo. We found a decreasing trend in newborns' weight (3089.8 ± 519.9 vs. 3346.3 ± 411.1 g, P = 0.05) and the rate of macrosomia (3.3% vs. 16.7%, P = 0.08) in the magnesium-zinc-calcium-vitamin D supplemented women. CONCLUSIONS: Overall, the findings of this study have demonstrated that magnesium-zinc-calcium-vitamin D co-supplementation for 6 weeks to women with GDM may reduce biomarkers of inflammation and oxidative stress. This study was retrospectively registered on 25 April 2017 in the Iranian website ( www.irct.ir ) for clinical trials registration ( http://www.irct.ir : IRCT201704225623N109).